DARLAN DA SILVA CANDIDO
Projetos de Pesquisa
Unidades Organizacionais
LIM/19 - Laboratório de Histocompatibilidade e Imunidade Celular, Hospital das Clínicas, Faculdade de Medicina
3 resultados
Resultados de Busca
Agora exibindo 1 - 3 de 3
conferenceObject CIRCULATING MIRNAS PROFILE AS POTENTIAL SIGNATURE OF BENZNIDAZOLE TREATMENT TOXICITY IN CHAGAS PATIENTS(2017) CANDIDO, Darlan da Silva; CUNHA-NETO, Edecio; RIGAUD, Vagner O.; OLIVEIRA, Lea C. de; MOREIRA, Carlos Henrique V.; JUNIOR, Nelson G.; SOUZA, Marcela de; SABINO, Ester C.; FERREIRA, Ludmila R.- Insect vectors of Chagas disease (Trypanosoma cruzi) in Northeastern Brazil(2018) FIDALGO, Arduina Sofia Ortet de Barros Vasconcelos; COSTA, Alanna Carla da; SILVA FILHO, José Damião da; CÂNDIDO, Darlan da Silva; FREITAS, Erlane Chaves; PEREIRA, Laíse dos Santos; ANDRADE, Mônica Coelho de; GOMES, Kátia Cristina Morais Soares; BEZERRA, Cláudia Mendonça; OLIVEIRA, Maria de FátimaAbstract INTRODUCTION: Chagas disease remains a public health problem in the rural and urban areas of 19 countries in the Americas. METHODS: The aim of the present study was to investigate the Trypanosoma cruzi infection rate of triatomines collected from both intra- and peridomiciliary areas in eleven municipalities of Southeastern Ceará, Brazil, from 2009 to 2015. RESULTS: A total of 32,364 triatomine specimens, including nymphs and adults, were collected, and 31,736 (98.06%) of these were examined. More nymphs were collected than adults, and the greatest number of triatomines (n = 8,548) was collected in 2010, for which the infection rate was 1.3%, with the highest rate of infections observed for specimens from Quixere. The species collected during the study were identified as Triatoma pseudomaculata, Triatoma brasiliensis, Panstrongylus megistus, Panstrongylus lutzi, and Rhodnius nasutus, with T. pseudomaculata being the most abundant (n = 19,962). CONCLUSIONS: These results verify the presence of triatomines in both intra- and peridomiciliary areas, thereby ensuring persistence of the pathogen and consequently, the disease, as the presence of infected vectors in households is an important risk factor. According to these findings, the Chagas Disease Control Program should intensify its efforts in order to prevent the spread of the disease.
- Pharmacotherapeutic follow-up of patients with Chagas disease using in use of benznidazole: drug-related problems and pharmaceutical interventions(2017) CORREIA, Joao Paulo Ramalho; COSTA, Alanna Carla da; ROCHA, Eduardo Arrais; QUIDUTE, Ana Rosa Pinto; CANDIDO, Darlan da Silva; PONCIANO, Angela Maria de Souza; FONTELES, Marta Maria de Franca; OLIVEIRA, Maria de FatimaIntroduction: Benznidazole (BNZ) is a drug available for the etiological treatment of Chagas disease. However, this drug is toxic and has a limited effectiveness on the chronic phase of this disease, often leading to poor treatment adherence. Methods: This is a descriptive and exploratory study conducted at the Pharmaceutical Care Service for Chagas disease patients of the Federal University of Ceara. Drug-related problems (DRPs) and pharmaceutical interventions (PIs) were classified according to the Second Consensus of Granada. Results: The average age of patients with Chagas disease was 62 years, with the majority residing in the Ceara countryside (86.7%), and having low education levels (63.3% with elementary school education). Regarding family income, most patients belonged to a household that earned <= 1-2 times the minimum wage per month. Approximately 73% of these patients complied with the BNZ treatment, and nearly 7% underwent therapy interruption after medical evaluation. A total of 189 DRPs were identified, of which 51.9% (n=98) were classified as potential, and 48.1% (n= 91) as actual. The most frequent DRPs were related to safety (qualitative safety; n=70; 37%), necessity (non-adherence; n=52; 27.5%), and effectiveness (qualitative effectiveness/non-optimal drug selection; n=45; 23.8%). Among the 216 PIs conducted, the majority were related to patient education (n=168; 77.8%) and pharmacological strategy (n=42; 19.4%). Conclusions: This study indicates the need for pharmacotherapeutic monitoring in patients with Chagas because of the high number of therapeutic interventions, DRPs (approximately 3 DRPs/patient), BNZ adherence, and polypharmacy.